LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK:GlaxoSmithKline plc said its experimental drug Bosatria has shown in a late-stage trial that it can help control the symptoms of a rare inflammatory condition. In the study, significantly more patients with hypereosinophilic syndrome were able to control their disease by taking Bosatria along with a reduced dose of a steroid drug - currently the only treatment option for this condition - when compared with people who received placebo.
